奥拉帕利(olaparib)、卢卡帕利(rucaparib)及尼拉帕利(niraparib)均为聚腺苷酸二磷酸核糖聚合酶抑制剂(PARPi)，是一类具有广阔发展前景的新型抗癌药物。PARPi通过靶向抑制细胞核内的聚腺苷酸二磷酸核糖聚合酶(PARP)，从而特异性杀死同源重组修复通路(homologous recombination repair pathway)缺陷的癌细胞。在我国，卢卡帕利已完成临床试验，奥拉帕利及尼拉帕利则于2019年被中国国家药品监督管理局(NMPA)正式批准，用于对铂类药物敏感的复发性卵巢癌患者的维持治疗。中国目前仍缺乏对此类药物的临床应用经验。这3种药物均已在美国、欧洲、中国香港地区上市，并已完成临床试验研究阶段。笔者拟就目前PARPi在卵巢癌治疗过程中的适用人群、疗效及安全性等研究现状进行详细阐述，旨在为PARPi在临床进一步推广、应用提供参考。

Poly ADP-ribose polymerase inhibitor (PARPi), such as olaparib, rucaparib and niraparib are brand-new anticancer drugs with great potential. Through targeting intranuclear poly ADP-ribose polymerase (PARP), PARPi, which have made remarkable achievements in treatment of cancers, have the unique ability to selectively kill cancer cells with deficiency of homologous recombination repair pathway. However, clinical trial of rucaparib has been completed in China, and olaparib and niraparib have been approved by the National Medical Products Administration (NMPA) of China in 2019 for maintenance treatment of patients with relapsed ovarian cancers. We are still lack of clinical experience in application of PARPi. This article aims to give a comprehensive description of the suitable population, efficacy and safety of PARPi in treatment of ovarian cancers, in order to provide reference for their following widespread use.